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Background: The adoptive transfer of allogeneic antiviral T lymphocytes derived from seropositive donors can
safely and effectively reduce or prevent the clinical manifestation of viral infections or reactivations in
immunocompromised recipients after hematopoietic stem cell (HSCT) or solid organ transplantation (SOT).
Allogeneic third party T-cell donors offer an alternative option for patients receiving an allogeneic cord blood transplant
or a transplant from a virus-seronegative donor and since donor blood is generally not available for solid
organ recipients. Therefore we established a registry of potential third-party T-cell donors (allogeneic cell registry,
alloCELL) providing detailed data on the assessment of a specific individual memory T-cell repertoire in response to
antigens of cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), and human herpesvirus (HHV) 6.
Methods: To obtain a manufacturing license according to the German Medicinal Products Act, the enrichment of
clinical-grade CMV-specific T cells from three healthy CMV-seropositive donors was performed aseptically under GMP
conditions using the CliniMACS cytokine capture system (CCS) after restimulation with an overlapping peptide pool
of the immunodominant CMVpp65 antigen. Potential T-cell donors were selected from alloCELL and defined as
eligible for clinical-grade antiviral T-cell generation if the peripheral fraction of IFN-γ+ T cells exceeded 0.03% of
CD3+ lymphocytes as determined by IFN-γ cytokine secretion assay.
Results: Starting with low concentration of IFN-γ+ T cells (0.07-1.11%) we achieved 81.2%, 19.2%, and 63.1%
IFN-γ+CD3+ T cells (1.42 × 106, 0.05 × 106, and 1.15 × 106) after enrichment. Using the CMVpp65 peptide pool for
restimulation resulted in the activation of more CMV-specific CD8+ than CD4+ memory T cells, both of which were
effectively enriched to a total of 81.0% CD8+IFN-γ+ and 38.4% CD4+IFN-γ+ T cells. In addition to T cells and NKT cells,
all preparations contained acceptably low percentages of contaminating B cells, granulocytes, monocytes, and NK
cells. The enriched T-cell products were stable over 72 h with respect to viability and ratio of T lymphocytes.
Conclusions: The generation of antiviral CD4+ and CD8+ T cells by CliniMACS CCS can be extended to a broad
spectrum of common pathogen-derived peptide pools in single or multiple applications to facilitate and enhance
the efficacy of adoptive T-cell immunotherapy.
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Infection or reactivation with cytomegalovirus (CMV),
Epstein-Barr virus (EBV), adenovirus (ADV), and human
herpesvirus (HHV) 6 are the most common causes of
viral morbidity and mortality after hematopoietic stem
cell transplantation (HSCT) or solid organ transplant-
ation (SOT) [1-9]. The lack or low frequency of antiviral
T cells and the delay in virus-specific T-cell reconstitu-
tion are critical factors in virally infected post-transplant
patients. Functionally active antiviral T cells are crucial
for the effective elimination and control of those life-
threatening viral infections or reactivations [10-12]. Treat-
ment with donor lymphocyte infusions (DLI) routinely
separated from the seropositive stem cell donor can im-
prove the clinical outcome of viral infection and leukaemia
relapse, but it is (i) associated with a high risk of inducing
graft-versus-host disease (GvHD), (ii) attended with im-
paired functionality of antiviral memory T cells in granulo-
cyte colony-stimulating factor- (G-CSF-) mobilized stem
cell donors [13-15], (iii) not suitable in high risk patients
with seronegative donors and (iv) not available for patients
receiving cord blood in HSCT or cadaveric transplants in
SOT. Recent studies have shown that the adoptive transfer
of T cells with selected antigen-specificities is an effective
and safe treatment option for enhancing the long-term
protection of patient immunity after engraftment and im-
mune reconstitution without increasing the risk of GvHD
[2-6,8,16-18]. The efficient treatment of high risk patients
with seronegative donors requires the rapid recruitment of
a suitable seropositive T-cell donor as well as an estab-
lished and robust protocol for the timely manufacturing of
antiviral T cells without long-term ex vivo stimulation.
One promising option for providing potential T-cell
donor is the allogeneic cell registry (alloCELL, www.
alloCELL.org), which was established at Hannover Medical
School within the last three years. The registry compiles
screening results on the specific memory T-cell repertoire
of potential donors in response to CMV, EBV, and ADV
[19] and is now extended to polyoma virus (BK) and
HHV6 [9] and thus will accelerate the adoptive T-cell ther-
apy. Currently the enrichment of clinical-grade antigen-
specific T cells from peripheral blood without long-term
ex vivo manipulation can be performed by two major prin-
ciples: the interferon-gamma (IFN-γ) based CliniMACS
cytokine capture system (CCS) and the reversible peptide-
MHC (pMHC) class I multimer technology. Both tech-
niques are already successfully used for the selection of
antiviral T cells in clinical settings [1-3,6-8,17,20,21]. The
CliniMACS CCS method has the advantage that instead of
single HLA-restricted peptides, recombinant proteins and
overlapping peptide pools not subjected to HLA restriction
can be used. These antigens enable the generation of a
broad repertoire of both CD8+ cytotoxic T cells (CTLs)
and CD4+ T helper (Th) cells specific to multiple epitopes[22]. Synthetic peptide pools covering the entire sequence
of a pathogen protein are most suitable for manufacturing
clinical-grade specific CD4+ and CD8+ T cells because
they can be produced and controlled more easily than
recombinant proteins under Good Manufacturing Practice
(GMP) conditions [23].
To obtain a manufacturing license according to the
German Medicinal Products Act (AMG) we first estab-
lished a reproducible protocol for the rapid manufacture
of clinical-grade T cells specific for CMV (Figure 1). Our
results suggest that sufficient numbers of functionally
active CMV-specific CD4+ and CD8+ T cells can be
activated by using the overlapping peptide pool of the
immunodominant CMV phosphoprotein 65 (pp65) as the
stimulating agent and efficiently enriched by CliniMACS
CCS with an adequate purity for adoptive T-cell transfer.
Methods
Allogeneic cell registry, alloCELL
Suitable third-party T-cell donors were selected from the
allogeneic cell registry alloCELL (www.alloCELL.org)
established at Hannover Medical School (MHH) as de-
scribed previously [19]. Informed consent was obtained
from all donors as approved by the Ethics Committee of
Hannover Medical School. All donors belong to the
active thrombocyte and blood donor pool of MHH’s
Institute for Transfusion Medicine and were typed for
HLA class I and class II alleles at the four-digit level
by sequence-based typing [24]. The ever-expanding
alloCELL registry documents specific so far T-cell fre-
quencies against different epitopes of CMV, EBV, ADV,
and HHV6 for 450 out of 1150 donors, best T-cell detec-
tion method, and results of functional and alloreactivity
assays. Donors are classified as high, low, and non-
responders according to the specific antiviral memory
T-cell frequencies as described by Sukdolak et al. [19].
Selection of a suitable CMV-specific T-cell donor
Three healthy donors with no acute infection and who
were determined to be eligible by national standards for
the donation of allogeneic blood products were selected
from alloCELL as potential candidates for T-cell dona-
tion. Selection was performed at first on the basis of the
CMV serostatus and the presence of CMV-specific T
cells as monitored by IFN-γ EliSpot assay in response to
the CMVpp65 overlapping peptide pool (CMVpp65pp)
and pMHC pentamer staining if the donor was HLA-
A*02:01-positive [13,19]. IFN-γ EliSpot assay was per-
formed with 2.5 × 105 peripheral blood mononuclear cells
(PBMCs)/well using 1 μg/ml per peptide of CMVpp65pp
(Miltenyi Biotec, Bergisch Gladbach, Germany) for restim-
ulation as described previously [19,25]. For a positive
response 10 spots per well (spw)/2.5 × 105 PBMCs were de-
fined as cut-off. In addition, for HLA-A*02:01-positive
Figure 1 Protocol for the rapid manufacture of clinical-grade antigen-specific T cells. A three-step protocol for the rapid generation of
clinical-grade antiviral T cells was established to facilitate the manufacture of specific T cells for adoptive transfer in pre-monitored patients. First
Step: Selection of potential T-cell donors from the alloCELL registry (HLA type, virus serology and virus-specific T-cell response). Second
Step: Verification of the donor’s specific T-cell frequencies (donor from alloCELL, stem cell or family donor) and prediction of the donor’s T-cell
enrichment efficiency by small-scale MiniMACS CSA. A T-cell donor is classified as eligible if (a) the peripheral frequency of virus-specific IFN-γ+ T
cells≥0.03% of total CD3+ T cells and (b) the restimulation efficiency is twice as much as the unstimulated control. Third Step: Manufacturing of
clinical-grade antiviral T cells by large-scale CliniMACS CCS. A CliniMACS CCS-enriched T-cell fraction (TCF) is classified as eligible if (a) number of
viable IFN-γ+ T cells >1 × 104 and (b) the number of viable IFN-γ− T cells≤2 × 107.
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by pMHC pentamer staining (Proimmune, Oxford,
UK; CMVpp65495–503, epitope NLVPMVATV, shortened
A02pp65M) as described in further studies [13,19].
To finally define these donors as suitable for clinical-
grade antiviral T-cell generation a detailed analysis of
antiviral T-cell frequencies was performed by cytokine
secretion assay (CSA). For recruitment, the starting fre-
quency of IFN-γ+ T cells had to exceed 0.03 of CD3+
lymphocytes and >2× the negative control value (cut-off
for positive response).
Detection of IFN-γ secreting CMV-specific T cells by
cytokine secretion assay
The non-GMP IFN-γ MiniMACS CSA (IFN-γ Secretion
Assay – Cell Enrichment and Detection Kit, Miltenyi
Biotec) was performed according to the manufacturer’s
instructions and was used: (1) to verify the startingfrequency of the donor’s CMV-specific memory T-cells,
(2) to predict the T-cell enrichment efficiency, and (3) as
a control in parallel to the clinical-scale CliniMACS
CCS enrichment procedure. By this the acceptability of
the starting leukapheresis material and non-specific
spontaneous release of IFN-γ in the unstimulated nega-
tive control was determined. PBMCs were cultured
ex vivo for four hours in T-CM alone (negative control),
with 1 μg/ml per peptide of the CMVpp65pp, and with
2 μg/ml staphylococcal enterotoxin B (positive control;
SEB, Sigma-Aldrich, Hamburg, Germany), respectively.
IFN-γ+ CMVpp65-specific T cells were specifically cap-
tured during the magnetic cell sorting (MACS) enrich-
ment processes by anti-IFN-γ-phycoerythrin (PE) antibody
and paramagnetic anti-PE mircobeads. The relevant
MiniMACS CSA cell fractions were used for a detailed
analysis of IFN-γ+ T-cell subsets. The distribution of vi-
able and dead cells in these fractions was analysed by
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Heidelberg, Germany). The percentage of viable IFN-γ+
cells was further analysed by staining the cells with
anti-CD45-allophycocyanin with cyanin-7 (APC/Cy7),
anti-CD56-phycoerythrin with cyanin-7 (PE/Cy7), and anti-
CD3-fluorescein isothiocyanate (FITC, all BD Biosciences)
mAbs. At least 10,000 events were acquired in the viable
CD45+ leukocyte gate for each analysis (FACSCantoII, BD
Biosciences). CD3+IFN-γ+, CD8+IFN-γ+ and CD4+IFN-γ+
T-cell populations were gated based on the scatter proper-
ties of viable 7AAD−CD45+CD56−CD3+ T lymphocytes.
Generation of clinical-grade CMV-specific T cells by
CliniMACS CCS
CMVpp65-specific T cells were enriched under GMP
conditions by using the IFN-γ CliniMACS Cytokine
Capture System (CliniMACS CCS) with the specified
components and reagents according to the manufac-
turer’s instructions (Miltenyi Biotec).
After washing the donor’s leukapheresis with CliniMACS
PBS/EDTA buffer, leukocytes were adjusted to a total of
2 × 109 leukocytes in 200 ml GMP compatible serum-free
TexMACS medium and stored overnight in 500 ml MACS
GMP Cell Differentiation Bags at 37°C and 5% CO2. Next
morning, a total of 1 × 109 leukocytes were used for
ex vivo stimulation with the GMP-grade CMVpp65 peptide
pool (CMVpp65pp, MACS GMP PepTivator HCMV pp65,
1 μg/ml per peptide) for four hours at 37°C. For control
MiniMACS CSA was performed in parallel with 1 × 107
leukocytes from the overnight incubation with the
CMVpp65pp. Enrichment of IFN-γ secreting leukocytes
during CliniMACS CCS was performed by immunomag-
netic separation using the CliniMACS Tubing Set and
the CliniMACS Cytokine Capture System, which con-
sisted of the CliniMACS Catchmatrix Reagent and
the CliniMACS IFN-γ Enrichment Reagent. CliniMACS
PBS/EDTA buffer was supplemented with 0.5% HSA
(human serum albumin) and used for all washing steps
and the elution of the final T-cell product. For cryo-
preservation the eluate fraction was adjusted to 2.86%
HSA, 7.5% DMSO (dimethyl sulfoxide), aliquoted, subse-
quently processed in a controlled-rate freezer, and finally
transferred to −140°C or lower in the vapour phase above
liquid nitrogen for long-term storage. A fully automated
microbial detection system was used for microbiological
testing (sterility) of the leukapheresis and the CliniMACS
CCS T-cell fraction. Total cell number and total viability
of the final T-cell product was determined by light mi-
croscopy using trypan blue. Due to the low cell numbers
in the final T-cell product, cell counting by light micros-
copy was performed by two staff members with each
counting 16 large scares. For all other process-attendant
cell fractions total cell number was counted by the full-
automated Hemocounter (Coulter ACTdiff, BeckmanCoulter), while total viability was analysed by flow cytome-
try (BD FACSCantoII) using 7AAD.
Quality control: assessment of the final T-cell product by
flow cytometry
Specific risk-based acceptance criteria were defined as
GMP-compliant prerequisites apart from the GMP-
compliant controlled manufacturing and testing environ-
ment (Additional file 1: Table S1). Criteria were defined
in consideration of published pre-clinical studies, statis-
tical inference, and the long-lasting expertise with already
established protocols for the generation of clinical-grade
cell products using CliniMACS technologies (e.g. selec-
tion of CD34+ cells). Samples of the following fractions
from CliniMACS CCS and MiniMACS CSA processes
were collected and analysed: leukapheresis, original frac-
tion (OF, after restimulation and before magnetic enrich-
ment), T-cell fraction (TCF, after magnetic enrichment),
waste fraction (WF, washing effluent) and negative frac-
tion (NF, cells not retained on the column). Additionally
the stability of the final product was assessed in ref-
erence samples stored for a total of 72 hours after leuka-
pheresis and analysed after 48 (stabi48), 54 (stabi54) and
72 (stabi72) hours (h).
Quality control (QC) of the enriched T-cell product
and the process-attendant fractions was performed to
assess the product characteristics of identity (frequencies
of CD3+IFN-γ+/− T-cell subsets), viability (total viabil-
ity, viable leucocytes and lymphocyte subsets), purity
(frequencies of contaminating cells), and IFN-γ secretion
as marker for potency. Three different marker panels
were established (Additional file 2: Table S2). (1) The
quality control panel A (QCP-A) was the major quality
control panel and was used for the specific identification
of viable IFN-γ+ T-cell frequencies (Figure 2). The panel
consisted of anti-CD45, anti-CD3, anti-CD56, anti-CD8,
and anti-IFN-γ mAB. To discriminate unspecific IFN-γ
staining a fluorescence minus one control (FMO, QCP-A−)
was performed. (2) For a detailed purity analysis staining
with anti-CD3, anti-CD56, anti-CD14, anti-CD33 and
anti-CD19 mAB was established (QCP-B). (3) The BD
FACSCantoII flow cytometer is limited to six colours.
Therefore anti-CD4 mAb could not be included in the
QCP-A, leading to the calculation of CD4+ T cells based
on the data obtained for CD3+ und CD8+ T cells. To con-
firm that this strategy is proper, a third panel (QCP-C)
containing anti-CD4 was utilised to proof if by the detec-
tion of CD3+ and C8+ T cells in the QCP-A the correct
number of CD4+ T cell can calculated. The data proved
that staining with anti-CD3 and anti-CD8 is sufficient to
reliably separate the CD3+CD4+ from the CD3+CD8+
T-cell population. Representative results for the TCF
are shown in Additional file 3: Table S3. A mean frequency
of 35.1 (range 24–55.9%) CD3+CD4+ T cells and 25.7%
Figure 2 Gating strategy established for flow cytometric quality and in-process control regarding the CliniMACS CCS validation.
Samples of the collected CliniMACS CCS fraction were analysed by flow cytometry using the Quality control panel QCP-A/A− and the represented
gating strategy. All cell fractions (leukapheresis, original fraction (OF), T-cell fraction (TCF), negative fraction (NF), waste fraction (WF), 48 h, 54 h,
and 72 h post-leukapheresis (Stabi48, Stabi54, and Stabi72)) were stained with specific antibodies to visualize IFN-γ+ T cells. In the first plot, cells
were analysed by 7AAD viability staining to determine the live versus dead cells, followed by gating cells based upon CD45 expression to identify
CD45+ leukocytes in the total viable 7AAD− population. In the next gating step, T cells were selected based on CD3 expression. CD3+CD56+ NKT
cells were gated out using a dump channel. CD4 and CD8 surface expression was then determined from this gated population. IFN-γ+ T cells
were gated on CD3+CD56− T cells and on the CD4+ and CD8+ subpopulation of CD3+CD56− T cells. The axes of the dot plots are biexponential.
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with QCP-A, while 34.4% CD3+CD4+ T cells (range 25–
52.3%) and 25.9% (range 7.31-56.7%) of CD3+CD8+ T cells
were quantified by using QCP-C. A notable low stand-
ard deviation was calculated between both staining
panels for CD3+CD4+ T cells (rangeSD 0.25-2.59%) and the
CD3+CD8+ T-cell subpopulation (rangeSD 0.03-0.22%), re-
spectively. Therefore, all further results shown here were
generated by using the results obtained using only theQCP-A. To provide the number of events for a valid qual-
ity control without compromising the therapeutic dose, in
future processes only QCP-A/A− and QCP-B will be used
routinely for in-process and quality control.
All analytic antibodies used for flow cytometry were
of in vitro diagnostic (IVD) quality. In the process-
attendant fractions leukapheresis, OF, and NF at least
50,000 events were acquired in the viable leukocytes gate
based on the light scatter properties of leukocytes and
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low cell numbers in the final TCF and the WF at least
10,000 events (10,000 – 50,000 events) were acquired
(Figure 2). Quality control of all collected fractions was
performed by using a gating strategy targeted to detect
and quantify IFN-γ+ T-cell subsets as well as contamin-
ating nonspecific IFN-γ− cells (Figure 2). CD3+IFN-γ+,
CD3+IFN-γ−, CD8+IFN-γ+, and CD4+IFN-γ+ T-cell pop-
ulations were gated based on the scatter properties of
viable T lymphocytes.
Statistical analysis
Statistical analysis was performed using the Prism soft-
ware v5.02 (GraphPad, San Diego, California, USA) to
analyse the process parameters relevant to quality and
the identity, purity, recovery, and viability. The results of
the statistical analysis are displayed in the tables and as
the mean ± SD in the Figures. Levels of significance were
expressed as p-values (*p < 0.05).
Results
Verification of CMVpp65-specific T-cell repertoire in
preselected T-cell donors from alloCELL registry
Three potential CMV-seropositive T-cell donors were re-
cruited from the alloCELL registry to validate the manu-
facturing of clinical-grade CMVpp65-specific T cells
(Table 1) according to their CMVpp65 memory T-cell
frequencies. Before starting the CliniMACS validation
processes, we assessed the data sets of the selected T-cell
donor’s CMVpp65-specificity from the alloCELL in a de-
tailed analysis (EliSpot assay, CSA, staining of T-cell sub-
sets, A02pp65M staining, Table 1). All three T-cell donors
were confirmed and defined to be eligible for T-cell do-
nation by CSA (CMVpp65pp, OFCD3+/IFN-γ+: mean 3.17%,
range 0.21-7.6%, TCFCD3+/IFN-γ+: mean 67.8%, range
38.4-89.6%). Leukapheresis products of these healthy
T-cell donors were used as starting materials in the valid-
ation of the GMP-compliant large-scale enrichment of
CMVpp65-specific T cells.
Validation of CMVpp65-specific T-cell enrichment by
CliniMACS CCS
Each CliniMACS CCS process (n = 3) resulted in the
collection of five fractions: leukapheresis, OF, TCF, WF
and NF. All leukapheresis averaged 23.9% CD3+CD56−
T cells (12.8-41.9%; Table 2A-C) with a mean viability of
99.6% (99.3-99.8%). The mean frequency of IFN-γ+ T
cells 0.07% (0.03-0.11%; Figure 3) indicating no relevant
T-cell activation in the native concentrates. Quality con-
trol of the OF before enrichment resulted in an IFN-γ+
T-cell frequency of 0.76% (range 0.07-1.11%) with a via-
bility of 98.3% (97.9-99.1%, Table 2A-C).
The TCF of the three validation runs contained 19.2-
81.2% CD3+IFN-γ+ T cells (0.05-1.42 × 106, mean 0.87 × 106)with a viability of 57.4% (range 51.1-62.1%; Table 2,
Figures 3 and 4A) in a total volume of 40–43 ml. A
frequency of 18.8-80.8% contaminating, potentially alloreac-
tive CD3+IFN-γ− T cells (0.23-0.67 × 106, mean 0.41 × 106)
was calculated. In relation to the number of CD3+IFN-γ+ T
cells determined in the OF, a 213-fold decrease (range 73-
369-fold) was observed in the TCF.
For the analysis of the enrichment efficiency by
CliniMACS CCS, the recovery of total CD3+IFN-γ+
T cells, CD4+IFN-γ+ T cells and CD8+IFN-γ+ T cells
(Figure 4B, Table 3) was calculated based on the percentage
of IFN-γ+ T cells in the CMVpp65pp-stimulated OF and
the enriched TCF. The recovery of total CD3+IFN-γ+ T
cells post-enrichment averaged 67.9 ± 22.7% (CD4+ IFN-γ+
T-cell recovery: 68.8 ± 57.2%, CD8+IFN-γ+ T-cell recovery:
57.2 ± 23.4%). Furthermore the CMVpp65-specific TCF
contained a mean of 54.5 ± 31.9% IFN-γ+ T cells with a
percentage of 38.4 ± 28% CD4+IFN-γ+ and 81 ± 15.8%
CD8+IFN-γ+ T cells. It was shown that 1 × 104 CD3+ Tcells
per kg body weight were efficient for adoptive transfer [8].
According to this, CliniMACS CCS enrichment resulted in
a sufficient number of total CD3+CD56− T cells as well as
total CD3+IFN-γ+ T cells for adoptive transfer in recipi-
ents up to 183 kg of body weight (validation run 3).
Moreover, the percentage of CD8+IFN-γ+ T cells was
higher than that of CD4+IFN-γ+ T cells (Figure 3A-C;
Table 2A-C) in all three performed CliniMACS CCS
validation runs.
As expected, a significantly lower number of IFN-γ+
T cells (frequency: 0.01-0.63%; total cell count: 0.01-
0.38 × 106; Figure 4A, Table 2) was found in the NF
compared to the respective TCF of all three runs. The
viability in the NF approximated 100% (range 98.2-
99.4%). During the process IFN-γ+ T cells were lost in
the WF in a much higher frequency than expected
(mean viability 94%; frequency IFN-γ+ T cells: 3.8-36.3%,
0.01-0.92 × 106; Figure 4A, Table 2). Leukapheresis prod-
ucts and TCFs of the three CliniMACS CCS validation
runs did not show contamination assessed by aerobic
and anaerobic cultures. Overall, the specific risk-based
acceptance criteria (Additional file 1: Table S1) were ful-
filled in all validation runs.
Stability evaluation of CliniMACS CCS-enriched T-cell
products
To determine the shelf life of the CMVpp65-specific
TCF, aliquots were stored in CliniMACS PBS/EDTA
buffer supplemented with 0.5% HSA over a total of 72 h
after leukapheresis at 2-6°C in the target fraction bag of
the CliniMACS tubing set as the primary container and
analysed kinetically (Table 4). The average recovery of
viability of stored TCFs was >100% for each defined time
point. Overall, a total of 4.57 × 106 viable leukocytes (viable
WBCs, range 3.6-6.2 × 106) with an average recovery
Table 1 Verification of CMV-specific T-cell frequencies in potential T-cell donors selected from the alloCELL registry
Donor
HLA-typing
alloCELL Verification and detailed analysis of CMV-specific memory T-cell frequencies
TCR-pMHC
interaction EliSpot Staining of T-cell subsets
TCR-pMHC
interaction CSA EliSpot
A B C DRB1 DQB1














1 *02:01 *68:01 *08:01 *39:01 *07:01 *12:03 *01:01 *03:01 *02:01 *05:01 2.45 273 78.88 52.47 41.24 1.5 1.7 75.48 236
2 *25:01 *32:01 *08:01 *35:01 *04:01 *07:01 *03:01 *14:01 *02:01 *05:03 n.a. 162 59.65 69.53 26.61 n.a. 0.21 38.39 178.4
3 *02:01 *11:01 *27:02 *55:01 *02:02 *03:03 *15:01 *16:01 *05:02 *06:02 0.31 142 63.79 68.41 26.7 0.34 7.6 89.63 306.5
Three potential T-cell donors we selected according to their CMV-seropositivity and CMVpp65-specific T-cell frequencies from the allogeneic cell registry alloCELL. For verification, PBMCs were isolated, T-cell subsets
were stained (% T cells [CD3, CD4 and CD8]) and CMVpp65-specific memory T cells were detected directly by pMHC pentamer staining using the A02pp65M (donor 1 and 3, % A02pp65M
+ /CD3+CD8+ T cells) and after a
short ex vivo stimulation with the CMVpp65pp by IFN-γ-based CSA (% CD3











Table 2 Outcome of CMVpp65-specific T-cell separation by CliniMACS CCS
A 1. Validation run
Leukapheresis OF TCF WF NF
volume [ml] 133 100 40 335 276
viability [%] 99.80 99.06 51.13 92.34 99.38
WBCs(CD45+) [x10
6/ml] 6.77 1.42 0.14 0.02 0.49
WBCsabs [x10
6] 900.41 142.00 5.51 8.15 136.07
T cells(CD3+CD56-) [% of WBCs] 41.93 47.80 31.68 41.58 44.55
T cells [/μl] 2834.59 680.00 43.50 10.12 219.57
T cellsabs [x10
6] 377.00 68.00 1.74 3.39 60.60
T cells(CD3+CD4+) [% of CD3
+] 53.00 50.82 26.20 49.74 51.01
T cells(CD3+CD8+) [% of CD3
+] 47.02 49.20 73.85 50.31 49.01
IFN-γ+ T cells [% of CD3+] 0.03 1.02 81.17 27.13 0.63
IFN-γ+ T cells [/μl] 0.85 6.94 35.50 2.74 1.38
IFN-γ+ T cells [x106] 0.11 0.69 1.42 0.92 0.38
IFN-γ− T cells [% of CD3+] 99.97 98.98 18.83 72.87 99.37
IFN-γ− T cells [/μl] 2834.59 673.00 8.20 7.37 218.12
IFN-γ− T cells [x106] 377.00 67.30 0.33 2.47 60.20
IFN-γ+ T cells(CD3+) [% of CD4] 0.02 0.29 12.91 6.36 0.17
IFN-γ+ T cells(CD3+CD4+)[% of CD4] 0.04 0.58 50.63 13.28 0.41
IFN-γ+ T cells(CD3+CD4+) [/μl] 0.60 2.00 5.78 0.67 0.46
IFN-γ+ T cellsabs (CD3+CD4+) [x10
6] 0.08 0.20 0.23 0.22 0.13
IFN-γ+ T cells(CD3+) [% of CD8] 0.01 0.71 67.96 20.49 0.40
IFN-γ+ T cells(CD3+CD8+)[% of CD8] 0.02 1.43 91.84 40.21 0.73
IFN-γ+ T cells(CD3+CD8+) [/μl] 0.27 4.79 29.50 2.04 0.79
IFN-γ+ T cellsabs (CD3+CD8+) [x10
6] 0.04 0.48 1.18 0.69 0.22
B 2. Validation run
Leukapheresis OF TCF WF NF
volume [ml] 114 100 40 337 288
viability [%] 99.31 98.07 62.05 99.27 98.83
WBCs(CD45+) [x10
6/ml] 18.77 2.36 0.03 0.00 0.66
WBCsabs [x10
6] 2133.91 236.00 1.06 0.69 190.94
T cells(CD3+CD56-) [% of WBCs] 16.97 36.69 27.92 25.73 41.15
T cells [/μl] 3175.44 865.00 7.43 0.53 272.92
T cellsabs [x10
6] 362.00 86.50 0.30 0.18 78.60
T cells(CD3+CD4+) [% of CD3
+] 71.57 62.28 78.45 69.19 62.36
T cells(CD3+CD8+) [% of CD3
+] 28.50 37.75 21.80 30.88 37.71
IFN-γ+ T cells [% of CD3+] 0.11 0.07 19.18 3.80 0.01
IFN-γ+ T cells [/μl] 3.50 0.61 1.42 0.02 0.03
IFN-γ+ T cells [x106] 0.40 0.06 0.05 0.01 0.01
IFN-γ− T cells [% of CD3+] 99.89 99.93 80.82 96.20 99.99
IFN-γ− T cells [/μl] 3175.44 864.00 6.00 0.51 272.92
IFN-γ− T cells [x106] 362.00 86.40 0.23 0.17 78.60
IFN-γ+ T cells(CD3+) [% of CD4] 0.07 0.02 4.95 1.51 0.01
IFN-γ+ T cells(CD3+CD4+)[% of CD4] 0.10 0.03 6.43 1.93 0.02
IFN-γ+ T cells(CD3+CD4+) [/μl] 2.27 0.16 0.38 0.01 0.03
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IFN-γ+ T cellsabs (CD3+CD4+) [x10
6] 0.26 0.02 0.02 0.00 0.01
IFN-γ+ T cells(CD3+) [% of CD8] 0.04 0.04 13.84 2.18 0.00
IFN-γ+ T cells(CD3+CD8+)[% of CD8] 0.12 0.10 62.96 6.52 0.00
IFN-γ+ T cells(CD3+CD8+) [/μl] 1.09 0.32 1.02 0.01 0.00
IFN-γ+ T cellsabs (CD3+CD8+) [x10
6] 0.12 0.03 0.04 0.00 0.00
C 3. Validation run
Leukapheresis OF TCF WF NF
volume [ml] 109 100 43 330 263
viability [%] 99.56 97.86 58.92 90.43 98.21
WBCs(CD45+) [x10
6/ml] 15.73 1.62 0.12 0.01 0.53
WBCsabs [x10
6] 1714.31 162.00 5.01 4.82 138.49
T cells(CD3+CD56-) [% of WBCs] 12.76 30.94 36.52 31.07 28.56
T cells [/μl] 2009.17 500.00 42.56 4.55 150.19
T cellsabs [x10
6] 219.00 50.00 1.83 1.50 39.50
T cells(CD3+CD4+) [% of CD3
+] 75.96 72.60 87.29 80.31 70.89
T cells(CD3+CD8+) [% of CD3
+] 24.08 27.43 12.81 19.71 29.13
IFN-γ+ T cells [% of CD3+] 0.06 1.11 63.13 36.29 0.47
IFN-γ+ T cells [/μl] 1.20 5.55 26.74 1.65 0.71
IFN-γ+ T cells [x106] 0.13 0.56 1.15 0.54 0.19
IFN-γ− T cells [% of CD3+] 99.94 98.89 36.87 63.71 99.53
IFN-γ− T cells [/μl] 2009.17 494.00 15.67 2.89 149.81
IFN-γ− T cells [x106] 219.00 49.40 0.67 0.95 39.40
IFN-γ+ T cells(CD3+) [% of CD4] 0.06 0.87 53.17 30.37 0.47
IFN-γ+ T cells(CD3+CD4) [% of CD4] 0.06 1.10 58.25 34.13 0.49
IFN-γ+ T cells(CD3+CD4+) [/μl] 0.91 3.99 21.63 1.24 0.52
IFN-γ+ T cellsabs (CD3+CD4+) [x10
6] 0.10 0.40 0.93 0.41 0.14
IFN-γ+ T cells(CD3+) [% of CD8] 0.02 0.30 11.48 7.75 0.10
IFN-γ+ T cells(CD3+CD8+)[% of CD8] 0.00 0.99 88.29 37.27 0.30
IFN-γ+ T cells(CD3+CD8+) [/μl] 0.00 1.36 4.81 0.33 0.13
IFN-γ+ T cellsabs (CD3+CD8+) [*10
6] 0.00 0.14 0.21 0.11 0.03
The purification of clinical-grade CMVpp65-specific CD4+ and CD8+ T cells from three healthy CMV-seropositive donors was performed aseptically under GMP
conditions using the IFN-γ-based CliniMACS CCS system and the GMP-compliant CMVpp65pp for short term ex vivo stimulation. Detailed information for all three
validation processes (A-B) including viability [%], viable cell number [x106/ml; x106; /μl] and specific cell frequencies [%] for all CliniMACS CCS fractions were
determined. The results for the representative analysis of the cells from the leukapheresis, original fraction (OF), T-cell fraction (TCF), negative fraction (NF), and
waste fraction (WF) are shown. Bold data reflected the results obtained for the CMV-specific IFN-γ-positive T cells.
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(viable T cells, range 0.25-2.09 × 106) with an average recov-
ery of 85% were found after 72 h post-leukapheresis.
The frequencies of CD3+CD56− T cells as well as
CD3+CD56−IFN-γ+/− T cells were stable (Figure 5). Sta-
bility analysis resulted in a recovery rate of 118% for vi-
able CD3+CD56− (79.48 to >100%), 120% for viable
CD3+CD56−IFN-γ+ T cells (84.25 to >100%), and viable
109% for CD3+CD56−IFN-γ− T cells (77.12 to >100%).
TCFs might contain cells which are still intact or on the
verge of apoptosis. During storage those cells may be lost
because of cell lysis resulting in recovery rates >100%.Enrichment of CMVpp65-specific T cells by non-GMP
MiniMACS CSA as a control process
The analogous parallel processing of CMVpp65-specific
T cells by non-GMP small-scale MiniMACS CSA re-
sulted in CD3+IFN-γ+ T-cell yields similar to those ob-
served in the CliniMACS CCS processes (Figures 3 and
4B, Tables 2 and 5). The first (69.3%, viability 15.6%;
Figure 3A, Table 5A) and the third (76.4%, viability
45.8%; Figure 3C, Table 5C) MiniMACS CSA process re-
sulted in ratios of IFN-γ+ T cells comparable to those
established by clinical-scale CliniMACS CCS. In the sec-
ond CliniMACS CCS validation run, a significantly lower
Figure 3 Flow cytometric quality and in-process control of
IFN-γ-based CliniMACS CCS enrichment of CMV-specific T cells.
IFN-γ+ CMV-specific T cells were isolated from leukapheresis by
large-scale GMP-grade CliniMACS CCS- and small-scale MiniMACS
CSA-based process. Flow cytometric analysis was performed with all
CliniMACS CCS and MiniMACS CSA fractions (leukapheresis, original
fraction (OF), T-cell fraction (TCF), negative fraction (NF), waste fraction
(WF), 48 h, 54 h, and 72 h post-leukapheresis (Stabi48, Stabi54,
and Stabi72)) by using the quality control panel (QCP) -A, QCP-B and
QCP-C-. The results of the representative analysis of the leukapheresis
and TCF by using the QCP-A panel are shown (n = 3). As a control the
QCP-A− was used as fluorescence minus one (FMO) for IFN-γ. Dot plots
show the qualitative analysis of IFN-γ-secreting CMV-specific T cells [%].
CD3+IFN-γ+ percentages were defined on viable CD3+ T cells, and
CD8+IFN-γ+ and CD4+IFN-γ+ percentages were defined on viable
CD4+ and viable CD8+ T-cells, respectively. IFN-γ−secreting T cells
are shown in the gate represented on each dot plot.
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to the small-scale MiniMACS CSA (19.2% vs. 59.6%;
viability 62.1% vs. 85.2%; Figure 3B, Tables 2B and 5B).
In addition to CMVpp65pp-restimulated T cells, SEB-
stimulated (PC, positive control) and unstimulated (NC,
negative control) T cells were used as controls in the
small-scale MiniMACS CSA (Table 5). Negative con-
trols resulted in significantly lower numbers of isolated
IFN-γ+ T cells (range 1.56-3.85%; viability 12.2-30%) com-
pared to the positive controls (range 60.8-82.3%, viability
33.2-89%).
Composition of leukocyte subsets of CliniMACS
CCS fractions
The composition of all fractions collected during the
CliniMACS CCS processes was evaluated in depth
with respect to the content of total CD3+, CD14+,
CD19+, CD33+, and CD56+ leukocytes using the QCP-B
(Figure 6). The most infrequent contaminants in the
TCF were CD3+CD56+ NKT cells (mean 0.22 × 105)
and CD3−CD56+ NK cells (mean 0.11 × 105). Further-
more, CD14+ monocytes (mean 1.46 × 106) , CD33
+ granu-
locytes (mean 0.9 × 106), and CD19+ B cells (mean 0.29 ×
106) represented the most common non-target cells
(Figure 6A). Nevertheless, the total number of these sub-
sets was decreased compared to the initial leukapheresis.
Highest log-depletion was observed for NK cells (4.57-
fold) and NKT cells (3.54-fold), respectively. B-cell num-
ber decreased 2.85-fold, followed by granulocytes (2.82-
fold), CD3+CD56− T cells (2.52-fold), and monocytes
(2.41-fold) (Figure 6B).
Discussion
A three-step protocol (Figure 1) for the rapid generation
of clinical-grade antiviral T cells was validated to facili-
tate the manufacture of specific T-cells, thereby allowing
a pre-emptive or prophylactic adoptive T-cell transfer.
Figure 4 Efficiency and outcomes of CliniMACS CCS validation for CMVpp65-specific T-cell enrichment. The percentage of IFN-γ secreting
CMVpp65-specific T cells was detected after four hours of ex vivo stimulation with CMVpp65pp using the QCP-A/A
- panel. The IFN-γ-based CliniMACS
CCS and MiniMACS CSA systems were used for the isolation of IFN-γ-secreting CMVpp65-specific T cells. (A) The numbers of IFN-γ+ cells [x106] within
the CD3, CD4 and CD8 T-cell populations were analysed in all collected CliniMACS CCS fractions (leukapheresis, original fraction (OF), T-cell fraction
(TCF), negative fraction (NF), waste fraction (WF), 48 h, 54 h, and 72 h post-leukapheresis (Stabi48, Stabi54, Stabi72)) to determine the efficiency of the
CliniMACS process. Data sets of the representative analysis of the leukapheresis, OF, TCF, NF, WF fractions are shown (B) Outcome of IFN-γ-based
CliniMACS CCS and MiniMACS CSA processes regarding the percentage [%] of IFN-γ+ cells among the CD3, CD4 and CD8 T-cell populations in
samples collected at different steps of the validation process (leukapheresis, OF, TCF, NF, WF, Stabi48, Stabi54, Stabi72). Data sets of the representative
analysis of the leukapheresis and TCF are shown. The results of independent experiments (n = 3) are expressed as the mean frequency of
IFN-γ+ T cells ± SD. Asterisks indicate statistically significant differences between samples before and after T-cell enrichment (*p < 0.05).
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The efficacy and safety of partially HLA-mismatched
third-party antiviral T-cell transfer has been demon-
strated in a number of studies, making the recruitment
of these donors a useful option for the effective treat-
ment of life-threatening infections or reactivation ofTable 3 Overall outcome of the CliniMACS CCS validation pro






Mean 67.86 68.81 57.20
SD 22.66 57.20 23.42
Median 77.69 69.95 70.37
Min 41.94 11.04 30.16
Max 83.94 125.43 71.08
The recovery of IFN-γ+ T cells [%] in the products after large-scale CliniMACS CCS e
(OF) and the final collected fractions (T-cell fraction (TCF), waste fraction (WF), nega
Stabi54, Stabi72)) as recovered from the CliniMACS tubing set. The result for the represe
post-CliniMACS CCS enrichment was calculated as the percentage of CD3+CD56− lymphcommon viruses such as CMV, EBV, ADV, or HHV6
[2,3,5-8,16,26]. The alloCELL registry established at the
Hannover Medical School represents a flexible platform
which facilitates the rapid identification and recruitment
of adequate donors according to HLA type, virus ser-









54.49 38.44 81.03 57.37
31.88 27.98 15.75 1.61
63.13 50.63 88.29 58.92
19.18 6.43 62.96 51.13
81.17 58.25 91.84 62.05
nrichment was calculated based on the CMVpp65pp-stimulated original fraction
tive fraction (NF), TCF after 48 h, 54 h, and 72 h post-leukapheresis (Stabi48,
ntative analysis of the recovery from the TCF is shown. The purity of IFN-γ+ T cells
ocytes [%]. Total viability was assessed by 7AAD viability staining.
Table 4 Analysis of product stability
Parameter Validation
run
TCF after enrichment 48 h 54 h 72 h
value recovery value recovery value recovery
WBC 1. run 1.43x107 9.60x106 67.00% 7.80x106 54.50% 7.60x106 53.10%
2. run 5.00x106 4.40x106 88.00% 4.20x106 84.00% 4.00x106 80.00%
3. run 1.25x107 8.60x106 69.00% 7.30x106 58.60% 6.50x106 51.70%
viable WBC 1. run 1.01x107 8.00x106 79.50% 7.20x106 71.60% 6.20x106 61.70%
2. run 3.40x106 3.20x106 94.10% 3.80x106 >100% 3.60x106 >100%
3. run 6.00x106 5.20x106 85.70% 4.30x106 71.40% 3.90x106 64.30%
viable T cells 1. run 1.74x106 1.42x106 81.61 1.32x106 75.86% 1.22x106 70.11%
2. run 2.97x106 2.17x105 73.06% 1.97x105 66.33% 2.49x105 83.84%
3. run 1.83x106 2.12x106 >100% 1.85x106 >100% 2.09x106 >100%
Stability of the cells from the T-cell fraction (TCF) was analysed after 48 h, 54 h and 72 h post-leukapheresis with respect to total numbers of WBCs [x106], viable
WBCs [x106] viable T cells (CD3+CD56− T cells) [x106], and recovery [%]. Detection of total cell numbers and viability was performed by light microscopy using
trypan blue dye.
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than 450 possible T-cell donors achieved by IFN-γ-based
immunoassays EliSpot, ICS and CSA as well as by spe-
cific TCR staining using pMHC multimers [19,25].
Second step (Verification of the donor’s specific T-cell
frequencies and prediction of the donor’s T-cell enrichment
efficiency by MiniMACS CSA)
In previous laboratory-scale MiniMACS CSA experi-
ments using CMVpp65pp, we demonstrated that donors
falling below a critical starting frequency of target cells
most likely result in a low purity of the enriched target
cell fraction. Therefore, donor eligibility (stem cell
donor, family donor as well as third party donor) was
subjected to lower limits of: (a) the peripheral frequencyFigure 5 Analysis of product stability. Stability of the TCF was
analysed after 48 h, 54 h and 72 h of the start of leukapheresis with
respect to product viability [%], frequency of CD3+CD56− T cells [%] in
CD45+ leukocytes and IFN-γ+/− T cells [%] in CD3+CD56− lymphocytes.
The results of independent experiments are expressed as the mean
frequency [%] of viability, T cells and IFN-γ+/− T cells with regard to the
different time points of storage.of virus-specific IFN-γ+ T cells (≥0.03% of total CD3+ T
cells) and of (b) the restimulation efficiency (twice as
much as the unstimulated control). We successfully
yielded highly pure CMVpp65-specific T cells from re-
cruited donors (Table 1), confirming the validity of data
provided by the alloCELL registry and the criteria for
T-cell donor eligibility.Third step (Manufacturing of clinical-grade antiviral
T cells by CliniMACS CCS)
The enrichment results determined in our study can
strongly be compared with recent studies demonstrating
the successful manufacture of highly pure antigen-specific
T cells by IFN-γ based CliniMACS CCS [3,6,7,27]. We
yielded IFN-γ+ T cells with a mean purity of 54.5 ± 31.9%,
which is comparable to data published for the enrichment
of CMV- (43.9-65% purity), EBV- (57% purity) and ADV-
specific (52–63.4% purity) T cells using the CliniMACS
CCS [1,3,4,6,8]. The quality of the final TCFs was success-
fully demonstrated by (1) IFN-γ secretion as potency
marker, (2) extensive flow cytometric quality control, and
(3) stability testing of the TCFs.Manufacture of clinical-grade antiviral T cells by
large-scale CliniMACS CCS
As an eligibility requirement for T-cell donor selection
the lower limit of the peripheral frequency of CMV-
specific IFN-γ+ T cells was defined with ≥0.03% of total
CD3+ T cells. For a variety of viruses including EBV,
ADV, and HHV6 the circulating precursor frequency of
reactive cells will likely be substantially lower than for
CMV. Therefore, the threshold of IFN-γ+ T cells has to be
determined for each pathogen-derived antigen. CliniMACS
CCS runs yielded purity grades (54.5 ± 31.9% viable
Table 5 Outcome of CMVpp65-specific T-cell separation by MiniMACS CSA
A 1. Validation run
Positive control CMVpp65pp Negative control
OF TCF OF TCF OF TCF
volume [ml] 0.6 1.0 0.6 1.0 0.6 1.0
viability [%] 98.81 33.19 98.70 15.63 98.67 12.21
WBCs(CD45+) [x10
6/ml] 42.70 0.07 47.50 0.01 39.50 0.00
WBCsabs [x10
6] 25.62 0.07 28.50 0.01 23.70 0.00
T cells(CD3+CD56-) [% of WBCs] 27.26 35.72 27.56 43.33 31.66 15.62
T cells [/μl] 11650.00 24.90 13100.00 6.23 12500.00 0.70
T cellsabs [x10
6] 6.99 0.02 7.86 0.01 7.50 0.00
T cells(CD3+CD4+) [% of CD3
+] 50.34 33.51 50.25 25.85 49.05 63.35
T cells(CD3+CD8+) [% of CD3
+] 49.67 66.51 49.77 74.15 50.97 36.71
IFN-γ+ T cells [% of CD3+] 0.69 82.33 0.23 69.27 0.01 2.89
IFN-γ+ T cells [/μl] 80.33 20.50 30.17 4.32 1.25 0.02
IFN-γ+ T cells [x104] 4.74 1.21 1.79 0.15 0.07 0.00
IFN-γ− T cells [% of CD3+] 99.31 17.67 99.77 30.73 99.99 97.11
IFN-γ− T cells [/μl] 11566.67 4.40 13066.67 1.92 12500.00 0.68
IFN-γ− T cells [x104] 682 026 778 0.07 724 0.02
IFN-γ+ T cells(CD3+) [% of CD4] 0.18 23.44 0.04 9.06 0.01 1.72
IFN-γ+ T cells(CD3+CD4+) [% of CD4] 0.37 70.45 0.09 35.32 0.01 2.82
IFN-γ+ T cells(CD3+CD4+) [/μl] 21.67 5.88 5.93 0.57 0.61 0.01
IFN-γ+ T cellsabs (CD3+CD4+) [x10
4] 1.28 0.35 0.35 0.02 0.04 0.00
IFN-γ+ T cells(CD3+) [% of CD8] 0.49 58.79 0.18 59.14 0.00 0.52
IFN-γ+ T cells(CD3+CD8+) [% of CD8] 0.95 87.52 0.37 78.94 0.00 1.42
IFN-γ+ T cells(CD3+CD8+) [/μl] 55.00 14.50 24.17 3.65 0.00 0.00
IFN-γ+ T cellsabs (CD3+CD8+) [x10
4] 3.24 0.86 1.44 0.13 0.00 0.01
B 2. Validation run
Positive control CMVpp65pp Negative control
OF TCF OF TCF OF TCF
volume [ml] 0.6 1.0 0.6 1.0 0.6 1.0
viability [%] 98.72 89.04 98.92 85.16 98.87 29.95
WBCs(CD45+) [x10
6/ml] 2.38 0.18 2.74 0.00 2.78 0.00
WBCsabs [x10
6] 1.43 0.18 1.64 0.00 1.67 0.00
T cells(CD3+CD56-) [% of WBCs] 95.94 88.43 89.37 68.87 88.83 55.91
T cells [/μl] 2283.33 162.00 2450.00 1.42 2466.67 11.10
T cellsabs [x10
6] 1.37 0.16 1.47 0.00 1.48 0.00
T cells(CD3+CD4+) [% of CD3
+] 71.87 75.54 71.00 43.38 69.45 71.15
T cells(CD3+CD8+) [% of CD3
+] 28.36 24.51 29.06 56.73 30.59 28.85
IFN-γ+ T cells [% of CD3+] 5.74 60.77 0.13 59.62 0.02 3.85
IFN-γ+ T cells [/μl] 131.00 98.30 3.18 0.85 0.49 0.43
IFN-γ+ T cells [x104] 7.86 9.83 0.19 0.08 0.03 0.00
IFN-γ− T cells [% of CD3+] 94.26 39.23 99.87 40.38 99.98 96.15
IFN-γ− T cells [/μl] 2150.00 63.50 2450.00 0.57 2466.67 10.70
IFN-γ− T cells [x104] 129 6.35 147 0.06 148 0.11
IFN-γ+ T cells(CD3+) [% of CD4] 3.83 43.77 0.07 14.53 0.02 1.92
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IFN-γ+ T cells(CD3+CD4+) [% of CD4] 4.99 56.07 0.06 32.76 0.03 2.70
IFN-γ+ T cells(CD3+CD4+) [/μl] 81.83 68.50 1.04 0.20 0.52 0.21
IFN-γ+ T cellsabs (CD3+CD4+) [x10
4] 4.91 6.85 0.06 0.02 0.03 0.00
IFN-γ+ T cells(CD3+) [% of CD8] 1.80 16.45 0.06 45.09 0.00 1.92
IFN-γ+ T cells(CD3+CD8+) [% of CD8] 5.75 64.53 0.21 78.34 0.00 6.67
IFN-γ+ T cells(CD3+CD8+) [/μl] 37.17 25.60 1.50 0.63 0.00 0.21
IFN-γ+ T cellsabs (CD3+CD8+) [x10
4] 2.23 2.56 0.09 0.06 0.00 0.00
C 3. Validation run
Positive control CMVpp65pp Negative control
OF TCF OF OF TCF OF
volume [ml] 0.6 1.0 0.6 1.0 0.6 1.0
viability [%] 98.57 69.24 98.87 45.75 98.63 26.57
WBCs(CD45+) [x10
6/ml] 4.23 0.02 3.33 0.01 3.66 0.00
WBCsabs [x10
6] 2.54 0.02 2.00 0.01 2.20 0.00
T cells(CD3+CD56-) [% of WBCs] 98.13 94.39 99.99 95.45 95.87 73.00
T cells [/μl] 4150.00 21.20 3333.33 11.90 3516.67 0.00
T cellsabs [x10
6] 2.49 0.02 2.00 0.01 2.11 0.00
T cells(CD3+CD4+) [% of CD3
+] 72.20 66.59 72.07 88.51 68.63 84.38
T cells(CD3+CD8+) [% of CD3
+] 27.80 33.41 27.93 11.49 31.37 15.62
IFN-γ+ T cells [% of CD3+] 2.73 70.70 1.49 76.41 0.00 1.56
IFN-γ+ T cells [/μl] 113.33 15.00 49.50 9.06 0.00 0.00
IFN-γ+ T cells [x104] 6.80 1.50 2.97 0.91 0.00 0.00
IFN-γ− T cells [% of CD3+] 97.27 29.30 98.51 23.59 100.00 98.44
IFN-γ− T cells [/μl] 4033.33 6.22 3283.33 2.80 3516.67 0.00
IFN-γ− T cells [x104] 242 0.62 197 0.28 211 0.00
IFN-γ+ T cells(CD3+) [% of CD4] 1.55 45.27 1.35 68.14 0.00 0.76
IFN-γ+ T cells(CD3+CD4+) [% of CD4] 2.17 67.26 1.83 76.52 0.00 1.04
IFN-γ+ T cells(CD3+CD4+) [/μl] 65.00 9.50 43.83 8.03 0.00 0.00
IFN-γ+ T cellsabs (CD3+CD4+) [x10
4] 3.90 0.95 2.63 0.80 0.00 0.00
IFN-γ+ T cells(CD3+) [% of CD8] 1.19 26.20 0.18 8.80 0.00 0.52
IFN-γ+ T cells(CD3+CD8+) [% of CD8] 4.33 81.11 0.72 78.15 0.00 3.33
IFN-γ+ T cells(CD3+CD8+) [/μl] 50.00 5.75 6.68 1.06 0.00 0.00
IFN-γ+ T cellsabs (CD3+CD8+) [x10
4] 3.00 0.58 0.40 0.11 0.00 0.00
The small-scale MiniMACS CSA was performed as a control for the large-scale CliniMACS CCS process from the same leukapheresis. Detailed information for all
three MiniMACS CSA processes (A-B) including viability [%], viable cell number [x106/ml; x106; /μl] and specific cell frequencies [%] for all CSA fractions was
determined. The results for the representative analysis of the cells from the original fraction (OF) and T-cell fraction (TCF) are shown. As a positive control, cells
were stimulated with SEB, while cells cultured in medium alone served as the negative control; CMVpp65pp = CMVpp65 peptide pool. Bold data reflected the
results obtained for the antigen-specific IFN-γ-positive T cells.
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studies [3,8].
The potency of antigen-specific IFN-γ+ T cells enriched
by CliniMACS CCS and MiniMACS CSA were studied by
several groups for various specificities (CMV, EBV, ADV,
Aspergillus) [6,22,28-33]. These studies described the se-
cretion of IFN-γ as suitable marker to determine the po-
tency of the final TCF. In a previous study we were able to
demonstrate that the isolation and enrichment did notalter the viability and antiviral T-cell function, observed by
T-cell’s degranulation capacity, proliferation and secretion
of the effector molecules IFN-γ, TNF-α and granzyme B
after in vitro expansion [28]. However, preclinical studies
with CliniMACS CCS-enriched T cells have demonstrated
a significant lower alloreactivity after co-incubation with
allogeneic APCs compared to unselected T cells. The loss
of alloreactivity evidenced a high specificity of the gener-
ated virus-specific T-cell product [3,22,31-34]. In addition,
Figure 6 Post-processing assessment of leukocyte subsets in the TCF. Fractions collected during the CliniMACS CCS process (leukapheresis,
original fraction (OF), T-cell fraction (TCF), negative fraction (NF), waste fraction (WF), 48 h, 54 h, and 72 h post-leukapheresis (Stabi48, Stabi54,
Stabi72)) were assessed for leukocyte subsets including: CD3+ T cells, CD3+CD56+ NKT cells, CD3−CD56+ NK cells, CD19+ B cells, CD33+ granulocytes and
CD14+ monocytes. (A) The compositions of the leukocyte subsets in the Leukapheresis products and the TCFs and (B) the log depletion in cell numbers
of leukocyte subsets after CliniMACS CCS enrichment are shown. The results of independent experiments are expressed as the number [x106] of IFN-γ+ T
cells ± SD and the fold decrease [log] of cell numbers in leukocyte subsets. Asterisks indicate statistically significant differences between T cells and other
leukocyte subsets (*p < 0.05).
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specific cytotoxic T cells was shown to not induce de novo
GvHD in the recipient the despite recognition of recipient
HLA molecules [26].
For transplantation with unmanipulated CD34+ cells
as well as DLIs a starting dose of <2.5 × 104 CD3+ T cells/
kg is recommended in a haploidentical setting and <105
CD3+ T cells/kg in a HLA-matched setting to reduce the
risk of inducing or enhancing GvHD [35]. In the post-
transplant setting to test efficacy and safety the same total
CD3+ T-cell safety limits will most likely apply to the adop-
tive T-cell transfer.
In the study of Peggs et al., CMV-specific T cells iso-
lated by CliniMACS CCS were used for adoptive transfer
with a target T-cell dose of 1 × 104 CD3+ T cells/kg of
recipient body weight, a mean number of 2840 CMV-
specific CD4+ T cells/kg body weight and 630 CMV-
specific CD8+ T cells/kg body weight [8]. Icheva et al.
2012 isolated EBV EBNA1-specific T cells by CliniMACS
CCS and used a mean number of 4.2x103 CD3+ T cells/kg
of recipient’s body weight with a mean number of 3613
EBV-specific CD4+ T cells/kg and 500 EBV-specific CD8+
T cells/kg for adoptive transfer [6]. In both studies, com-
parably low numbers of adoptively transferred antiviral
CD3+ T cells were sufficient for the life-saving treatment.
In addition, we analysed the contribution of viable
leukocyte subsets (CD3+CD56+ NKT cells, CD14+ mono-
cytes, CD33+ granulocytes, CD19+ B cells, and CD3−CD56+
NK cells in the leukapheresis and the final TCF (Figure 6).
It is likely that these contaminants were specificallycaptured during the CliniMACS CCS enrichment pro-
cesses because of their ability to secret IFN-γ. Neverthe-
less, due to the in vitro antigen restimulation the total
number of each analysed leukocyte subset is reduced in
the final TCF (Figure 6). To gain more insight into the role
of contaminating cell subsets in the TCF, the type and
number of contaminants will be further investigated.
The enrichment of IFN-γ-positive T cells also resulted
in (1) the enrichment of dead cells causing a comparably
low viability (CliniMACS: 57.4 ± 5.62%) and (2) higher
percentages of IFN-γ+ T cells in the WF than expected.
Overall, little is known about the impact of dead adop-
tively transferred leukocytes. Despite the fact that the
three validation runs performed complied with the de-
fined acceptance criteria (Additional file 1: Table S1),
improvement of the T-cell product’s viability is of great
importance to provide sufficient numbers of functional
active antiviral T cells. The use of the fully automated
CliniMACS Prodigy (Miltenyi Biotec) might overcome
these problems by e.g. shortening the process time to
approximately 12 hours. Comparing the performance of
the Prodigy with the CliniMACS CCS procedure will
yield information on the viability, purity, and recovery of
the enriched T-cell products.
Some circumstances might prevent the infusion of the
antiviral TCF immediately after manufacture, including:
(1) long-range logistics or (2) treatment plan-related is-
sues, i.e., delayed infusion because of immediate life-
saving procedures or repeated dosage schemes. Therefore
we investigated stability of the TCF up to a period of 72 h
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Aliquots and reference samples of the three products were
cryopreserved and stored in the gas phase above liquid ni-
trogen at < −160°C for subsequent stability testing and the
validation of the cryopreservation process.
Role of antigenic stimuli, T-cell subsets and T-cell numbers
The CMVpp65 peptide pool consists of 15-mer peptides
of overlapping sequence spanning the whole viral target
protein and enables the simultaneous induction of spe-
cific CD4+ and CD8+ T cells, irrespective of the HLA type
[23,25,36,37]. As expected a higher HLA class I-restricted
antigen-specific CD8+ T-cell response than for CD4+ T
cells was observed.
It is not really clear yet what is the best ratio of anti-
viral CD4+ and CD8+ T cell to improve the efficacy of
this procedure and clinical outcome. Feuchtinger and
colleagues have analysed the number of naive, central
memory, and effector memory T cells among IFN-γ-
secreting CMVpp65-specific T cells in the TCF obtained
via CliniMACS CCS enrichment [3]. They successfully
identified that the largest subpopulation in the T-cell
products is formed by T cells of late effector stages. This
subset was detectable over six months after T-cell trans-
fer and seems to be responsible for the long-lasting
CMVpp65-specific T-cell immunity in transplant recipi-
ents. Moreover, many groups have shown that CD62L+
memory T cells may represent a suitable donor T-cell
subpopulation for enhancing immune reconstitution and
providing long-lasting immunity without increasing the
risk of GvHD [3,38-40]. For this reason, it is of great im-
portance to monitor the specific cellular immunity in
patients before and after adoptive T-cell transfer in rela-
tion to the phenotype and quantities of transferred spe-
cific CD4+ and CD8+ T cells.
Conclusions
Treatment of high-risk patients requires the efficient
and rapid manufacture of virus-specific T cells without
long-term ex vivo stimulation, while still maintaining
antiviral CD8+ and CD4+ T cells including the rapid re-
cruitment of specific seropositive T-cell donors with at
least 3/6 HLA-matches to the patient. The manufacture
of antiviral T cells using the CliniMACS CCS was vali-
dated at Hannover Medical School. By using the immu-
nodominant CMVpp65 overlapping peptide pool during
three independent CliniMACS CCS validation runs, a
three-step protocol with standard criteria for donor se-
lection and the rapid manufacturing of clinical-grade T
cells was successfully designed to covering the entire
procedure of antiviral T-cell generation for clinical appli-
cations. The accelerated selection and recruitment of
third-party T-cell donors with adequate frequencies of
virus-specific memory T cells from the alloCELL registryin the first two steps of the protocol will be feasible in
less than three days at best, while clinical-grade T cells
can be separated in less than 36 hours, thus allowing a
short-term initiation of adoptive immunotherapy.
We separated the quality control into QC release cri-
teria and additional report only analyses for our scien-
tific “add on” (advanced characteristic) program. For this
reason a product release document, which provides the
release relevant product parameters: viability, total vol-
ume of the preparation, sterility, purity, percentage and
cell numbers of IFN-γ+ as well as contaminating IFN-γ−
T cells was established. T-cell dose for adoptive transfer
will be calculated regarding to the individual clinical re-
quirements (e.g. differences between haploidentical and
HLA-matched application).
The use of the IFN-γ-based CliniMACS CCS for spe-
cific T-cell enrichment offers a great flexibility by using
any possible antigen of interest and results in products
that are sufficiently uniform with regards to T-cell purity
and in the depletion of unspecific IFN-γ− T cells. The
enrichment of virus-specific CD4+ and CD8+ T cells
seems to be of great relevance for viral clearance and
the long-lasting control of viral infections in a post-
transplant setting. In addition, the established T-cell manu-
facturing protocol can be easily adapted to enrich T cells
restricted against other pathogens such as EBV, ADV,
HHV6 and Aspergillus and can be extended to melanoma
(Melan-1/Mart-1) and tumor antigens (WT1).
Adoptive immunotherapy has become a valuable clin-
ical extension to existing treatments. In the future it will
be important to routinely monitor the patient’s cell-
mediated immunity to identify high-risk patients who
need adoptive T-cell transfer as a prophylactic treatment
to improve their clinical outcome. Harmonization of
risk-based and product release acceptance criteria be-
tween different GMP facilities will be helpful to identify
the most relevant once. Increasing the availability of clin-
ical safety and efficacy data for adoptive immunotherapy
will help to define the clinical requirements (e.g., patient
condition, T-cell frequency, optimal time point of transfer,
viability and purity of the antiviral T-cell product) for an
effective and safe therapeutic approach.
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